You are here: Industry Insights > T2D

News List

Oramed Initiates Phase 3 Trial of Oral Insulin americanpharmaceuticalreview
December 11, 2020
Oramed Pharmaceuticals has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
T2D market will grow from a total of $48.1bn sales in 2019 to $91.9 bn in 2029 expresspharma
November 18, 2020
T2D market growth factors are increasing diagnosed prevalence of disease and emergence of novel pipeline agents.
Forxiga Approved in the EU for Heart Failure americanpharmaceuticalreview
November 13, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D).
SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData expresspharma
September 16, 2020
Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further complications such as major adverse cardiac events.
Biocon and Voluntis deal to transform insulin biosimilars personalised care through digital therapeutics: GlobalData expresspharma
July 31, 2020
Biocon plans to create a comprehensive digital therapeutics portfolio by extending its Insulia platform to its complete range of insulin products.
Consuming Ultraprocessed Food May Up Risk for Type 2 Diabetes drugs
December 17, 2019
Ultraprocessed food (UPF) consumption is associated with an increased risk for type 2 diabetes (T2D), according to a study published online in JAMA Internal Medicine.
Type 2 Diabetes Linked to Colorectal Cancer Risk in Men drugs
December 06, 2018
Type 2 diabetes (T2D) is associated with an increased risk for colorectal cancer (CRC), with the association significant for men only, according to a study published online Nov. 7 in the British Journal of Cancer.....
FDA OKs J&J's Invokana for heart conditions biospectrumasia
November 26, 2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved INVOKANA (canagliflozin) to reduce the risk
Johnson & Johnson backs new Invokana CV nod with series of awareness tweets fiercepharma
November 15, 2018
ohnson & Johnson’s new Invokana cardiovascular indication is getting a Twitter assist. J&J is using the social media platform to get the word out about the link between Type 2 diabetes and cardiovascular risks...

Previous page 1 2 Next page